ORIGINAL ARTICLESEfficacy and safety of roflumilast in the treatment of asthma
REFERENCES (31)
The size of the problem of managing asthma
Respir Med
(2004)- et al.
Marginal utility of montelukast for persistent asthma
Chest
(2002) - et al.
The molecular biology of cyclic nucleotide phosphodiesterases
Prog Nucleic Acid Res Mol Biol
(1999) Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
Biochem Pharmacol
(1999)- et al.
Therapeutic potential of selective PDE inhibitors in asthma
Pulm Pharmacol Ther
(1999) - et al.
Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions
J Allergy Clin Immunol
(2005) - et al.
A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma
Chest
(2000) - et al.
Pharmacology of airway inflammation in asthma and COPD
Pulm Pharmacol Ther
(2003) - et al.
Asthma and allergy: a worldwide problem of meanings and management?
Allergy
(2002) Global strategy for asthma management and prevention: workshop report, October 2005
Effects of inhaled corticosteroids, leukotriene receptor antagonists, or both, plus long-acting β2-agonists on asthma pathophysiology: a review of the evidence
Drugs
Modulation of inflammation and immunity by cyclic AMP
Science
Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms
Physiol Rev
Cyclic nucleotide phosphodiesterases: relating structure and function
Prog Nucleic Acid Res Mol Biol
Phosphodiesterase isozymes: molecular targets for novel antiasthma agents
Am J Respir Crit Care Med
Cited by (84)
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19
2020, European Journal of PharmacologyCurrent insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS
2020, International ImmunopharmacologyJAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease
2018, Annals of Allergy, Asthma and ImmunologyRoflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma
2016, Journal of Allergy and Clinical ImmunologyRoflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies
2015, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Since asthma is a heterogeneous disease it is not surprising that anti-inflammatory treatments with different mechanisms of action are beneficial both as monotherapy and when combined, and the search for additional options has resulted in the development of a variety of classes of treatment, including phosphodiesterase-4 inhibitors [4,5], monoclonal antibodies, IgE, and other inflammatory targets [5]. As described in companion papers in this edition of the journal (Meltzer et al., Placebo-controlled studies and Bardin et al., Mechanism of Action studies), the pharmacology and mechanism of action of the oral phosphodiesterase-4 inhibitor roflumilast and its confirmed role in the management of COPD (it is approved in patients with severe COPD associated with chronic bronchitis and a history of exacerbations), support a potential role for it in the treatment of asthma [6,7]. The indication in severe chronic obstructive pulmonary disease (COPD) is as an add-on treatment for patients with symptoms of chronic bronchitis and a history of frequent exacerbations.
This study was sponsored by ALTANA Pharma AG, Konstanz.